The GLP-1 Provider Report: Testing, Price, Fulfillment and Customer Experience Compared

The GLP-1 telehealth market is structurally different from the research-chemical market, and we score it differently in emphasis if not in method. Providers here dispense through licensed pharmacies following a clinician consultation. The compound itself is usually less of a question than it is elsewhere. What varies enormously is everything around it: what you are actually prescribed, what you pay, how long it takes to arrive, and whether anyone answers when something goes wrong.

We evaluated 3 providers on the same six Index Score™ dimensions we apply to every company, and independently tested 26 dispensed samples. 25 of those (96%) met their label claims on purity and content.

Product quality, in other words, was largely fine. That is the expected result when product moves through licensed pharmacies rather than gray-market synthesis, and it is worth stating plainly rather than manufacturing alarm about it.

The differentiation sits elsewhere. Across the providers we evaluated, Customer Experience scores span a range of 3 points and Fulfillment spans 7. Those are enormous gaps for what is nominally the same service. The practical difference between the top and bottom of this table is whether a delayed shipment during a titration schedule gets resolved in a day or in three weeks.

The issue we would flag hardest is the compounded-versus-branded distinction. Some providers dispense FDA-approved branded product. Some dispense compounded semaglutide or tirzepatide prepared by a 503A or 503B pharmacy. These are not equivalent, they are not regulated equivalently, and the difference is frequently soft-pedalled in marketing copy that emphasises the active ingredient and skips the manufacturing chain. A patient should know which one they are being sold before they pay, and on several of the sites we reviewed, they would have to work to find out.

Pricing is similarly opaque by design. Headline monthly figures routinely exclude the consultation fee, assume a starting dose that most patients titrate off within eight weeks, or require a multi-month prepayment to access. We score Value on total verified cost of a realistic course, not the advertised entry price, which is why some of the loudest discounters do not score well on it.

Our overall read: this is a better-functioning market than the research-chemical channel, with a real regulatory floor under the product. The problems here are commercial and informational rather than chemical, which makes them more tractable, and makes the providers that handle them well genuinely worth identifying.